Onxeo to Attend Key Investor and Partnering Conferences in H1 2018

Onxeo today announced that its management team will attend the following key investor and partnering conferences in the first half of 2018.

Paris (France), January 3, 2018 - 5:45 pm CET - Onxeo, a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced that its management team will attend the following key investor and partnering conferences in the first half of 2018:

  • Investor meetings during the JP Morgan Healthcare Conference 2018

January 8-11, 2018

San Francisco, US

  • ODDO BHF Forum

January 12, 2018

Lyon, France

  • BIO-Europe Spring

March 12-14, 2018

Amsterdam, The Netherlands

  • CM-CIC Market Solutions Forum by ESN

March 22-23, 2018

Paris, France

  • Portzamparc MidCap 2018 Conference

April 4-5, 2018

Paris, France

  • BIO International Convention

June 4-7, 2018

Boston, US

  • SG CIB Nice Conference 2018

June 7-8, 2018

Nice, France

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today.  The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Onxeo's R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors.  Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo's partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form). 

Onxeo is also developing AsiDNA™, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already successfully completed a Phase I trial in metastatic melanoma via local administration, and is currently being developed for systemic (IV) administration in solid tumors.

AsiDNA™ is the first compound generated from platON™, the Company's proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. PlatON™ will continue to generate new compounds that will broaden Onxeo's pipeline.

For further information, please visit www.onxeo.com.

MORE ON THIS TOPIC